Osteoporosis

June 2017
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Regul Toxicol Pharmacol. 2017;86:356-365. Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G.

April 2017
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial.
Bone. 2017;97:314-319. Moreira C, Fitzpatrick LA, Wang Y, Recker RR.

February 2017
Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial.

Mayo Clin Proc. 2017;92:200-210. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Bone. 2017;95:143-150. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.

January 2017
One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption.
J Bone Miner Res. 2017;32:24-33. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G.

Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors.
J Bone Miner Res. 2017;32:17-23. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM.

November 2016
Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats.
Calcif Tissue Int. 2016;99:489-499. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G.

August 2016
Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.

JAMA. 2016;316:722-733. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

January 2016
Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling.
Endocrinology. 2016;157:141-149. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ.

February 2015
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2015;100:697-706. Leder BZ, O’Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

Oncology

May 2017
Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.
Clin Cancer Res. 2017 May 4 [online ahead of print]. Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown J, Purandare DM, Hattersley G, Garner F.

October 2015
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Anticancer Drugs. 2015;26(9):948-56. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G.